Evofem reports 2024 net sales up 6% to $19.4M; operating loss improved 57% YoY

Evofem Biosciences, Inc.

2024 net sales $19.4M (+6% YoY); operating loss $7.7M vs $17.8M in 2023, improvement of 57%.
Q4 2024 net sales $7.1M vs $4.8M Q4 2023; Q4 operating loss $1.0M vs $3.4M.
Sales & marketing expense fell to 47% of net sales for FY2024, down from 64% in 2023.
Merger with Aditxt: $1.5M funding due by Apr 7, 2025; stockholder meeting by Sep 26, 2025; close by Sep 30, 2025.
Raised $2.7M from Aditxt in Oct 2024; used to pay FDA obligations; year-end restricted cash $0.7M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.